Publicaciones en colaboración con investigadores/as de Pfizer (United States) (9)

2011

  1. Inappropriate overuse of inhaled corticosteroids for COPD patients: Impact on health costs and health status

    Lung, Vol. 189, Núm. 3, pp. 199-206

  2. Risk factors for asthma onset between the ages of 12 and 40. results of the FENASMA study

    Archivos de Bronconeumologia, Vol. 47, Núm. 9, pp. 433-440

2010

  1. The influence of heart disease on characteristics, quality of life, use of health resources, and costs of COPD in primary care settings

    BMC Cardiovascular Disorders, Vol. 10

2009

  1. Characteristics of chronic obstructive pulmonary disease in Spain from a gender perspective

    BMC Pulmonary Medicine, Vol. 9

  2. Health, treatment and health care resources consumption profile among Spanish adults with diabetes and chronic obstructive pulmonary disease

    Primary Care Diabetes, Vol. 3, Núm. 3, pp. 141-148

2008

  1. Determinants and predictors of the cost of COPD in primary care: A Spanish perspective

    International Journal of COPD, Vol. 3, Núm. 4, pp. 701-712

2003

  1. Safety and effectiveness of replacing standard doxazosin with doxazosin in the gastrointestinal therapeutic system (GITS) formulation in elderly hypertensive patients

    International Journal of Clinical Practice, Vol. 57, Núm. 4, pp. 267-272

2002

  1. A postmarketing, open-label study to evaluate the tolerability and effectiveness of replacing standard-formulation doxazosin with doxazosin in the gastrointestinal therapeutic system formulation in adult patients with hypertension

    Clinical Therapeutics, Vol. 24, Núm. 5, pp. 786-797

2000

  1. Drug surveillance study of amlodipine in patients with hypertension not controlled with drug therapy: NORCON study

    Current Therapeutic Research - Clinical and Experimental, Vol. 61, Núm. 12, pp. 863-870